ABVC BioPharma Reports $1.28 Million in Q3 Licensing Revenue, Strengthening High-Margin Business Model
ABVC BioPharma has collected $1.28 million in Q3 licensing revenues from multiple partners, including OncoX BioPharma, demonstrating the profitability of its licensing framework with minimal incremental costs.
ABVC BioPharma has received a licensing payment of $145,950 from OncoX BioPharma, bringing total receipts from OncoX in the third quarter to $595,950. This contributes to the company's consolidated licensing revenues of $1,275,950 for Q3 2025 across multiple strategic partnerships, including AiBtl BioPharma and ForSeeCon Eye Corporation.
The licensing revenue stream represents a high-margin business model for ABVC, as these payments carry minimal incremental operating costs since development expenses were largely incurred in prior years. These revenues directly strengthen the company's cash position and profitability profile. According to Dr. Uttam Patil, ABVC's Chief Executive Officer, these milestone revenues underscore the strength and reliability of the company's licensing framework while contributing to its high-margin profile and long-term growth strategy.
OncoX BioPharma, a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotheraparies derived from natural sources, currently has four IND-approved oncology assets licensed from ABVC. The company is actively expanding its portfolio, including the anticipated acquisition of the Lycogen® lycopene platform, which is projected to reach a global market size of $187 million by 2030 according to Allied Market Research.
The total potential deal proceeds from the OncoX partnership could reach $105 million if all milestone payments are achieved, though the company notes there can be no guarantee of such outcomes. OncoX operates under a strategic collaboration with BioKey Inc., a U.S. FDA-registered facility, and seeks to expand its global footprint with development and commercialization plans in the United States, Japan, Taiwan, and other key Asia-Pacific markets.
ABVC BioPharma maintains an active pipeline of six drugs and one medical device under development, utilizing in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. The company's forward-looking statements caution that actual results may differ materially from expressed expectations due to various risks and uncertainties, including manufacturing challenges, financing difficulties, competition changes, and regulatory approval processes. More detailed information is available in the company's filings with the Securities and Exchange Commission at http://www.sec.gov.